PSMA-targeted radioligand therapy outcomes vary by patient characteristics and disease burden in metastatic castration-resistant prostate cancer
Prior chemo and liver spread worsen outcomes for prostate cancer patients on PSMA therapy
A systematic review and meta-analysis of 4,819 patients with metastatic castration-resistant prostate cancer reveals that prior chemotherapy…
A large review of 4,819 patients found that prior chemotherapy and liver spread worsen survival. This helps doctors predict who benefits mos…
Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
New drug treatment lowers death risk for advanced prostate cancer patients by thirty seven percent
This phase 3 randomized controlled trial enrolled 472 European patients with metastatic hormone-sensitive prostate cancer. Darolutamide 600 …
A large study found that adding darolutamide to standard care helped European patients live longer and delayed cancer growth. Serious side e…
PSMA PET Parameters Predict Survival in mCRPC on Lu-PSMA-617
PSMA PET scan numbers may help predict Lu-PSMA therapy response in prostate cancer
Meta-analysis of 23 studies shows PSMA PET parameters, especially tumor volume, predict survival in mCRPC patients treated with Lu-PSMA-617.
A meta-analysis of 23 studies suggests certain PSMA PET scan measurements might help predict how patients with metastatic prostate cancer re…
Narrative review discusses LPA signaling in advanced prostate cancer
LPA signaling pathway offers new hope for advanced prostate cancer treatment
This narrative review examines lysophosphatidic acid metabolism and signaling in patients with advanced prostate cancer. The authors discuss…
A review discusses how targeting lysophosphatidic acid signaling might help patients with advanced prostate cancer, though more research is …
Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer
Darolutamide plus ADT improves survival in advanced prostate cancer patients
This systematic review and meta-analysis of randomized controlled trials evaluated darolutamide combination therapy versus placebo plus ADT …
A large analysis of trials shows darolutamide combined with standard treatment extends life and delays cancer spread in advanced prostate ca…
Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
Prostate Cancer Drug Helps Men Live Years Longer, New Data Shows
This post hoc analysis of a phase 3 randomized controlled trial in 1150 patients with metastatic hormone-sensitive prostate cancer found tha…
Men with advanced prostate cancer who took enzalutamide lived years longer than those on standard treatment alone, according to five-year da…
Enzalutamide plus radium-223 extends survival in metastatic castration-resistant prostate cancer
Adding Radium-223 to enzalutamide extends life for advanced prostate cancer patients
This phase 3 randomized controlled trial in 446 patients with metastatic castration-resistant prostate cancer compared enzalutamide plus rad…
Adding a specific bone-targeting drug to standard treatment helps men with advanced prostate cancer live longer while managing side effects …
Darolutamide plus ADT delays pain progression in metastatic hormone-sensitive prostate cancer
New treatment delays pain in advanced prostate cancer
This randomised, double-blind, phase 3 trial in men with metastatic hormone-sensitive prostate cancer found that darolutamide plus androgen …
Men with advanced prostate cancer who took darolutamide stayed pain-free longer and felt better overall for months compared to those on stan…
EC1169 and 99mTc-EC0652 show increased bone lesion detection and longer rPFS in mCRPC patients
A new prostate cancer drug shows promise but has limited activity in this early trial
This Phase I study evaluated EC1169 and 99mTc-EC0652 in 103 patients with metastatic castration-resistant prostate cancer.
A new prostate cancer drug detected bone lesions better than standard scans and linked to longer survival in early testing.
Niraparib plus abiraterone and prednisone shows mixed results in HRR-mutated mCRPC
New drug combo extends life for some prostate cancer patients
This retrospective cohort study of 5 patients with HRR-mutated metastatic castration-resistant prostate cancer evaluated niraparib plus abir…
Some men with advanced prostate cancer are living longer with a powerful new drug combo, even when they’re older or too weak for harsh treat…
Phase 2 trial of pembrolizumab and DNA vaccines in metastatic prostate cancer shows no significant difference
Prostate Cancer Vaccine Strategy Shows Tumor Responses, But One Arm Adds Risk
This early Phase 2 trial evaluated pembrolizumab combined with pTVG-HP or pTVG-AR DNA vaccines in 60 patients with metastatic castration-res…
A two-vaccine strategy did not improve survival over a single vaccine in advanced prostate cancer, yet both approaches shrank tumors in some…
Meta-analysis associates emerging lesions after lutetium-177 therapy with worse overall survival in mCRPC
Emerging lesions on scans linked to lower survival in prostate cancer patients
This systematic review and meta-analysis evaluated interim post-treatment SPECT/CT findings in 648 patients with metastatic castration-resis…
New spots appearing on scans after treatment for advanced prostate cancer are linked to significantly lower survival rates.
Research across Cancer
Related studies from across the Cancer family.
Hypofractionated and dose-boosted radiotherapy improves metastasis-free survival in clinically localised prostate cancer
Dose-boosting radiotherapy may improve survival for high-risk prostate cancer patients
This systematic review and meta-analysis evaluated hypofractionated and dose-boosted radiotherapy fractionation schedules versus standard ra…
Combining external beam radiotherapy with brachytherapy or a focal boost significantly improved metastasis-free survival in patients with cl…
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77
Statins lower recurrence and death risk in hormone receptor-positive breast cancer
This systematic review and meta-analysis evaluated statin use versus non-use in 267,913 patients with hormone receptor-positive breast cance…
A massive analysis of over 267,000 patients shows statins reduce recurrence and death risk in hormone receptor-positive breast cancer.
Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
Immunotherapy shows mixed results for hormone-positive breast cancer patients
This systematic review and meta-analysis evaluated immunotherapy in patients with hormone receptor-positive and human epidermal growth facto…
A large analysis found immunotherapy did not improve overall survival but did increase side effects for hormone-positive breast cancer patie…
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Intensity-modulated radiotherapy reduces acute and delayed G2+GI toxicities versus 3D-CRT in high-risk prostate cancer
Post hoc analysis shows IMRT reduces radiation side effects for high-risk prostate cancer
This post hoc analysis of a Phase III randomized controlled trial evaluated intensity-modulated radiotherapy (IMRT) versus three-dimensional…
A post hoc analysis of a Phase III trial found that intensity-modulated radiotherapy reduced radiation side effects compared to older techni…
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Time to biochemical progression predicts second events in high-risk prostate cancer
Longer time to progression predicts better outcomes in prostate cancer
This phase 3 RCT of 413 men with high-risk localized prostate cancer found that a longer time from randomization to biochemical progression …
Men with high-risk prostate cancer who had a longer time before their cancer worsened were less likely to have further progression or spread…
Systematic review and meta-analysis evaluates PRIMARY score on PSMA PET for prostate cancer detection
PRIMARY Score Finds Hidden Cancer With High Accuracy
This systematic review and meta-analysis of 1974 patients evaluated the diagnostic accuracy of the PRIMARY score on PSMA PET/CT or PET/MRI f…
A new scan reading tool catches most dangerous prostate cancers with high accuracy for men who have never had a biopsy.
Ultrasound-guided salvage brachytherapy with interstitial hyperthermia shows low toxicity in locally recurrent prostate cancer
New prostate cancer treatment shows low side effects after 5 years
This prospective phase 2 trial evaluated ultrasound-guided salvage brachytherapy with interstitial hyperthermia in 109 patients with locally…
A new treatment for recurrent prostate cancer kept 93% of patients alive at 5 years with very low serious side effects.
Online adaptive MRI-guided SBRT showed technical feasibility in intermediate-risk prostate cancer patients
New MRI-guided radiation technique works for most intermediate-risk prostate cancer patients
This Phase 2 non-randomized trial evaluated online adaptive magnetic resonance imaging (MRI)-guided stereotactic body radiation therapy in 5…
A new radiation method delivered the right dose to tumors in 85% of patients with intermediate-risk prostate cancer. This approach uses onli…
Systematic review finds neoadjuvant chemohormonal therapy improves biochemical progression-free survival in locally advanced prostate cancer
Chemo Before Prostate Surgery Linked to Better Cancer Control
This systematic review and meta-analysis evaluated neoadjuvant chemohormonal therapy (NCHT) combined with radical prostatectomy versus radic…
Patients with advanced prostate cancer may see better cancer control with chemo before surgery, though survival gains need more proof.
Questions about metastatic hormone-sensitive prostate cancer
Can darolutamide plus ADT delay pain progression in metastatic hormone-sensitive prostate cancer?
Yes, darolutamide plus ADT significantly delays pain progression in metastatic hormone-sensitive prostate cancer, based on the ARANOTE phase 3 trial.
Full answer →Does darolutamide combination therapy improve survival for metastatic hormone-sensitive prostate cancer?
Yes, darolutamide combination therapy improves survival in metastatic hormone-sensitive prostate cancer, with a 32% reduction in risk of death when added to ADT plus docetaxel.
Full answer →All metastatic hormone-sensitive prostate cancer Articles
- PSMA-targeted radioligand therapy outcomes vary by patient characteristics and disease burden in metastatic castration-resistant prostate cancer
- PSMA PET Parameters Predict Survival in mCRPC on Lu-PSMA-617
- Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
- Narrative review discusses LPA signaling in advanced prostate cancer
- Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer
- Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
- Enzalutamide plus radium-223 extends survival in metastatic castration-resistant prostate cancer
- Darolutamide plus ADT delays pain progression in metastatic hormone-sensitive prostate cancer
- EC1169 and 99mTc-EC0652 show increased bone lesion detection and longer rPFS in mCRPC patients
- Niraparib plus abiraterone and prednisone shows mixed results in HRR-mutated mCRPC
- Phase 2 trial of pembrolizumab and DNA vaccines in metastatic prostate cancer shows no significant difference
- Meta-analysis associates emerging lesions after lutetium-177 therapy with worse overall survival in mCRPC
- Systematic review of PSMA-directed CAR-T therapy for mCRPC highlights barriers and emerging platforms
- Deutenzalutamide improves rPFS in mCRPC after abiraterone and docetaxel progression
- FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for PSMA-positive metastatic castration-resistant prostate cancer
- Olaparib plus durvalumab showed activity in mCRPC patients previously treated with abiraterone or enzalutamide
- Lu-PSMA-617 reduces disease progression versus deferred ADT in oligometastatic HSPC in phase 2 trial
- Lu-PSMA-617 plus pembrolizumab shows PSA response in mCRPC phase 1b/2 trial
- Synchronous bone-metastatic prostate cancer incidence 6% with median survival of 43 months in Chinese cohort
- CDSS Dashboard Implementation Associated with Higher CRPC Detection in Prostate Cancer Cohort
- Phase II study of 177Lu-PSMA-617 in mCRPC shows 50% PSA response and median OS of 18.8 months
- Meta-analysis finds 47% PSA decline >50% with Ac-225/Lu-177 PSMA combination in mCRPC